Biblio

12 resultats trouvés
Filtres: Auteur is Scherpereel, Arnaud  [Clear All Filters]
A
Scherpereel A, Durand-Zaleski I, Cotte F-E, Fernandes J, Debieuvre D, Blein C, Gaudin A-F, Tournier C, Vainchtock A, Chauvin P et al..  2018.  Access to innovative drugs for metastatic lung cancer treatmentin a French nationwide cohort: the TERRITOIRE study. BMC CANCER. 18:1013.
C
Christodoulou M, Blackhall F, Ashcroft L, Leylek A, Knegjens J, Remouchamps V, Martel-Lafay I, Farre N, Zwitter M, Lerouge D et al..  2017.  Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial. JOURNAL OF THORACIC ONCOLOGY. 12:S262-S263.
Christodoulou M, Blackhall F, Mistry H, Leylek A, Knegjens J, Remouchamps V, Martel-Lafay I, Farre N, Zwitter M, Lerouge D et al..  2019.  Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. JOURNAL OF THORACIC ONCOLOGY. 14:63-71.
D
Chouaid C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin A-F, Ozan N, Saitta B et al..  2015.  Disparities in Lung Cancer Incidence and Management Care in France: A Nationwide Cohort Study (the TERRITOIRE Study). JOURNAL OF THORACIC ONCOLOGY. 10:S226-S227.
Chouaid C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin A-F, Ozan N, Saitta B et al..  2015.  Disparities in Lung Cancer Incidence and Management Care in France: A Nationwide Cohort Study (the TERRITOIRE Study). JOURNAL OF THORACIC ONCOLOGY. 10:S226-S227.
F
Couraud S, Ferretti G, Milleron B, Cortot A, Girard N, Gounant V, Laurent F, Leleu O, Quoix E, Revel M-P et al..  2021.  Francophone intergroup of thoracic cancerology, French language pneumology society, and Thoracic imaging society statement paper on lung cancer screening. DIAGNOSTIC AND INTERVENTIONAL IMAGING. 102:199-211.
H
Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Lena H et al..  2019.  Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. CLINICAL CANCER RESEARCH. 25:5759-5765.
I
Westeel V, Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O et al..  2018.  Impact on health-related quality of life of the addition of bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS phase III trial.. JOURNAL OF CLINICAL ONCOLOGY. 36
Derosa L, Routy B, Thomas AMaltez, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F et al..  2022.  Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. NATURE MEDICINE. 28:315+.
S
Souquet PJean, Durand-Zaleski I, Chouaid C, Debieuvre D, Scherpereel A, Fernandes J, Westeel V, Blein C, Gaudin A-F, Leblanc S et al..  2017.  Socioeconomic Determinants of Late Diagnosis of Lung Cancer in France: A Nationwide Study (the TERRITOIRE Study). JOURNAL OF THORACIC ONCOLOGY. 12:S306.
Souquet PJean, Durand-Zaleski I, Chouaid C, Debieuvre D, Scherpereel A, Fernandes J, Westeel V, Blein C, Gaudin A-F, Leblanc S et al..  2017.  Socioeconomic Determinants of Late Diagnosis of Lung Cancer in France: A Nationwide Study (the TERRITOIRE Study). JOURNAL OF THORACIC ONCOLOGY. 12:S306.
Chouaid C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin A-F, Ozan N, Leblanc S et al..  2017.  Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study). PLOS ONE. 12:e0182798.